摘要
目的探讨艾迪注射液联合吉非替尼治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效及对血清肿瘤标志物的影响。方法选取2016年6月至2017年9月医院肿瘤内科收治的NSCLC患者103例,随机分为对照组(51例)和观察组(52例)。对照组患者单纯给予吉非替尼口服治疗,观察组患者给予艾迪注射液联合吉非替尼治疗。结果治疗后,观察组疾病控制率及有效率均明显优于对照组(P<0.05);观察组炎性因子[白细胞介素2(IL-2)、白细胞介素12(IL-12)和γ干扰素(IFN-γ)]水平均明显高于对照组(P<0.05),肿瘤标志物[癌胚抗原(CEA)、肿瘤抗原125(CA125)及血管内皮生长因子(VEGF)]水平均明显低于对照组(P<0.05);两组均无严重不良反应,组间不良反应发生率比较无明显差异(P>0.05)。结论艾迪注射液联合吉非替尼治疗NSCLC疗效明显,对肿瘤标志物影响较大,能提高治疗有效率及患者的免疫功能。
Objective To investigate the clinical effect of Aidi Injection Combined with gefitinib in the treatment of non-small cell lung cancer（NSCLC） and its effect on serum tumor markers. Methods Totally 103 NSCLC patients admitted to our hospital from June2016 to September 2017 were randomly divided into the control group（n = 51） and the observation group（n = 52） according to the random number table method. The control group was treated with gefitinib alone,while the observation group was treated with Aidi Injection combined with gefitinib. Results After treatment,The disease control rate and effective rate in the observation group were significantly better than those in the control group（P〈0. 05）. The levels of inflammatory factors（IL-2,IL-12,IFN-γ） in the observation group were significantly higher than those in the control group（P〈0. 05）,while the levels of CEA,CA125 and VEGF in the observation group were significantly lower than those in the control group（P〈0. 05）. There was no serious adverse reaction in the two groups,and there was no significant difference in the incidence rate of adverse reactions between the two groups（P〉0. 05）.Conclusion Aidi Injection combined with gefitinib in the treatment of NSCLC has obvious curative effect on tumor markers,which can improve the effective rate of treatment and immune function of patients.
作者
汪桃利
欧阳郴生
杨丽娜
陈钟
古宏晖
Wang Taoli;Ouyang Chensheng;Yang Lina;Chen Zhong;Gu Honghui(The Fourth Clinical Medicine College of Guangzhou University of Chinese Medicine,Shenzhen,Guangdong,China 518033)
出处
《中国药业》
CAS
2018年第12期32-35,共4页
China Pharmaceuticals
基金
广东省科技计划项目[2017A020213017]
2015年广东省深圳市科技研发资金知识创新计划第二批基础研究项目[220]
关键词
艾迪注射液
吉非替尼
非小细胞肺癌
疗效
肿瘤标志物
免疫功能
Aidi Injection
gefitinib
non - small cell lung cancer
curative effect
tumor markers
immune function
